Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study
Abstract Background This study aimed to evaluate the efficacy and the safety of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing neutropenia in metastatic colorectal cancer (mCRC) patients that received fluorouracil, leucovorin, oxaliplatin, and irinote...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-04-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-020-06864-8 |
| _version_ | 1818850141641113600 |
|---|---|
| author | Yusuke Kitagawa Hiroki Osumi Eiji Shinozaki Yumiko Ota Izuma Nakayama Takeshi Suzuki Takeru Wakatsuki Mariko Ogura Akira Ooki Daisuke Takahari Mitsukuni Suenaga Keisho Chin Kensei Yamaguchi |
| author_facet | Yusuke Kitagawa Hiroki Osumi Eiji Shinozaki Yumiko Ota Izuma Nakayama Takeshi Suzuki Takeru Wakatsuki Mariko Ogura Akira Ooki Daisuke Takahari Mitsukuni Suenaga Keisho Chin Kensei Yamaguchi |
| author_sort | Yusuke Kitagawa |
| collection | DOAJ |
| description | Abstract Background This study aimed to evaluate the efficacy and the safety of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing neutropenia in metastatic colorectal cancer (mCRC) patients that received fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab (Bev) in clinical practice. Methods We retrospectively analyzed mCRC patients who received FOLFOXIRI plus Bev between December 2015 and December 2017. We evaluated the efficacy of PEG-G-CSF as preventing or treating grade 3 or 4 neutropenia, the overall response rate (ORR) according to the Response Evaluation Criteria in Solid Tumors version 1.1, progression-free survival (PFS), overall survival (OS), and adverse events of FOLFOXIRI plus Bev based on the Common Terminology Criteria for Adverse Events version 4.0. Results A total of 26 patients (median age 53.5 years) were included. The ORR rate was 65.3%, the median PFS was 9.6 months (7.2–16.9), and the median OS was 24.2 months (13.6–NA). Grade 3 or 4 neutropenia occurred in 53.8% of the patients, and febrile neutropenia occurred in 7.7%. PEG-G-CSF was given to 77.0% of the patients, including prophylactically (n = 9) and after the development of grade 3 or 4 neutropenia (n = 11). No patients experienced grade 3 or 4 neutropenia after the administration of PEG-G-CSF. In seven of the nine patients who received PEG-G-CSF prophylactically (77.8%), no dose adjustment was required. Conclusions PEG-G-CSF is useful in preventing severe neutropenia in mCRC patients treated with FOLFOXIRI plus Bev. |
| first_indexed | 2024-12-19T06:44:25Z |
| format | Article |
| id | doaj.art-7d20c8a497de4f959dc09cfaba009269 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-19T06:44:25Z |
| publishDate | 2020-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-7d20c8a497de4f959dc09cfaba0092692022-12-21T20:31:57ZengBMCBMC Cancer1471-24072020-04-012011910.1186/s12885-020-06864-8Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective studyYusuke Kitagawa0Hiroki Osumi1Eiji Shinozaki2Yumiko Ota3Izuma Nakayama4Takeshi Suzuki5Takeru Wakatsuki6Mariko Ogura7Akira Ooki8Daisuke Takahari9Mitsukuni Suenaga10Keisho Chin11Kensei Yamaguchi12Department of Gastroenterology, The Cancer Institute Hospital, Japanese Foundation for Cancer ResearchDepartment of Gastroenterology, The Cancer Institute Hospital, Japanese Foundation for Cancer ResearchDepartment of Gastroenterology, The Cancer Institute Hospital, Japanese Foundation for Cancer ResearchDepartment of Gastroenterology, The Cancer Institute Hospital, Japanese Foundation for Cancer ResearchDepartment of Gastroenterology, The Cancer Institute Hospital, Japanese Foundation for Cancer ResearchDepartment of Gastroenterology, The Cancer Institute Hospital, Japanese Foundation for Cancer ResearchDepartment of Gastroenterology, The Cancer Institute Hospital, Japanese Foundation for Cancer ResearchDepartment of Gastroenterology, The Cancer Institute Hospital, Japanese Foundation for Cancer ResearchDepartment of Gastroenterology, The Cancer Institute Hospital, Japanese Foundation for Cancer ResearchDepartment of Gastroenterology, The Cancer Institute Hospital, Japanese Foundation for Cancer ResearchDepartment of Gastroenterology, The Cancer Institute Hospital, Japanese Foundation for Cancer ResearchDepartment of Gastroenterology, The Cancer Institute Hospital, Japanese Foundation for Cancer ResearchDepartment of Gastroenterology, The Cancer Institute Hospital, Japanese Foundation for Cancer ResearchAbstract Background This study aimed to evaluate the efficacy and the safety of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing neutropenia in metastatic colorectal cancer (mCRC) patients that received fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab (Bev) in clinical practice. Methods We retrospectively analyzed mCRC patients who received FOLFOXIRI plus Bev between December 2015 and December 2017. We evaluated the efficacy of PEG-G-CSF as preventing or treating grade 3 or 4 neutropenia, the overall response rate (ORR) according to the Response Evaluation Criteria in Solid Tumors version 1.1, progression-free survival (PFS), overall survival (OS), and adverse events of FOLFOXIRI plus Bev based on the Common Terminology Criteria for Adverse Events version 4.0. Results A total of 26 patients (median age 53.5 years) were included. The ORR rate was 65.3%, the median PFS was 9.6 months (7.2–16.9), and the median OS was 24.2 months (13.6–NA). Grade 3 or 4 neutropenia occurred in 53.8% of the patients, and febrile neutropenia occurred in 7.7%. PEG-G-CSF was given to 77.0% of the patients, including prophylactically (n = 9) and after the development of grade 3 or 4 neutropenia (n = 11). No patients experienced grade 3 or 4 neutropenia after the administration of PEG-G-CSF. In seven of the nine patients who received PEG-G-CSF prophylactically (77.8%), no dose adjustment was required. Conclusions PEG-G-CSF is useful in preventing severe neutropenia in mCRC patients treated with FOLFOXIRI plus Bev.http://link.springer.com/article/10.1186/s12885-020-06864-8FOLFOXIRI plus bevacizumabNeutropeniaPolyethylene glycol conjugated granulocyte colony-stimulating factor |
| spellingShingle | Yusuke Kitagawa Hiroki Osumi Eiji Shinozaki Yumiko Ota Izuma Nakayama Takeshi Suzuki Takeru Wakatsuki Mariko Ogura Akira Ooki Daisuke Takahari Mitsukuni Suenaga Keisho Chin Kensei Yamaguchi Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study BMC Cancer FOLFOXIRI plus bevacizumab Neutropenia Polyethylene glycol conjugated granulocyte colony-stimulating factor |
| title | Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study |
| title_full | Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study |
| title_fullStr | Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study |
| title_full_unstemmed | Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study |
| title_short | Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study |
| title_sort | clinical utility of polyethylene glycol conjugated granulocyte colony stimulating factor peg g csf for preventing severe neutropenia in metastatic colorectal cancer patients treated with folfoxiri plus bevacizumab a single center retrospective study |
| topic | FOLFOXIRI plus bevacizumab Neutropenia Polyethylene glycol conjugated granulocyte colony-stimulating factor |
| url | http://link.springer.com/article/10.1186/s12885-020-06864-8 |
| work_keys_str_mv | AT yusukekitagawa clinicalutilityofpolyethyleneglycolconjugatedgranulocytecolonystimulatingfactorpeggcsfforpreventingsevereneutropeniainmetastaticcolorectalcancerpatientstreatedwithfolfoxiriplusbevacizumabasinglecenterretrospectivestudy AT hirokiosumi clinicalutilityofpolyethyleneglycolconjugatedgranulocytecolonystimulatingfactorpeggcsfforpreventingsevereneutropeniainmetastaticcolorectalcancerpatientstreatedwithfolfoxiriplusbevacizumabasinglecenterretrospectivestudy AT eijishinozaki clinicalutilityofpolyethyleneglycolconjugatedgranulocytecolonystimulatingfactorpeggcsfforpreventingsevereneutropeniainmetastaticcolorectalcancerpatientstreatedwithfolfoxiriplusbevacizumabasinglecenterretrospectivestudy AT yumikoota clinicalutilityofpolyethyleneglycolconjugatedgranulocytecolonystimulatingfactorpeggcsfforpreventingsevereneutropeniainmetastaticcolorectalcancerpatientstreatedwithfolfoxiriplusbevacizumabasinglecenterretrospectivestudy AT izumanakayama clinicalutilityofpolyethyleneglycolconjugatedgranulocytecolonystimulatingfactorpeggcsfforpreventingsevereneutropeniainmetastaticcolorectalcancerpatientstreatedwithfolfoxiriplusbevacizumabasinglecenterretrospectivestudy AT takeshisuzuki clinicalutilityofpolyethyleneglycolconjugatedgranulocytecolonystimulatingfactorpeggcsfforpreventingsevereneutropeniainmetastaticcolorectalcancerpatientstreatedwithfolfoxiriplusbevacizumabasinglecenterretrospectivestudy AT takeruwakatsuki clinicalutilityofpolyethyleneglycolconjugatedgranulocytecolonystimulatingfactorpeggcsfforpreventingsevereneutropeniainmetastaticcolorectalcancerpatientstreatedwithfolfoxiriplusbevacizumabasinglecenterretrospectivestudy AT marikoogura clinicalutilityofpolyethyleneglycolconjugatedgranulocytecolonystimulatingfactorpeggcsfforpreventingsevereneutropeniainmetastaticcolorectalcancerpatientstreatedwithfolfoxiriplusbevacizumabasinglecenterretrospectivestudy AT akiraooki clinicalutilityofpolyethyleneglycolconjugatedgranulocytecolonystimulatingfactorpeggcsfforpreventingsevereneutropeniainmetastaticcolorectalcancerpatientstreatedwithfolfoxiriplusbevacizumabasinglecenterretrospectivestudy AT daisuketakahari clinicalutilityofpolyethyleneglycolconjugatedgranulocytecolonystimulatingfactorpeggcsfforpreventingsevereneutropeniainmetastaticcolorectalcancerpatientstreatedwithfolfoxiriplusbevacizumabasinglecenterretrospectivestudy AT mitsukunisuenaga clinicalutilityofpolyethyleneglycolconjugatedgranulocytecolonystimulatingfactorpeggcsfforpreventingsevereneutropeniainmetastaticcolorectalcancerpatientstreatedwithfolfoxiriplusbevacizumabasinglecenterretrospectivestudy AT keishochin clinicalutilityofpolyethyleneglycolconjugatedgranulocytecolonystimulatingfactorpeggcsfforpreventingsevereneutropeniainmetastaticcolorectalcancerpatientstreatedwithfolfoxiriplusbevacizumabasinglecenterretrospectivestudy AT kenseiyamaguchi clinicalutilityofpolyethyleneglycolconjugatedgranulocytecolonystimulatingfactorpeggcsfforpreventingsevereneutropeniainmetastaticcolorectalcancerpatientstreatedwithfolfoxiriplusbevacizumabasinglecenterretrospectivestudy |